Researchers of the Josep Carreras Leukaemia Research Institute have discovered an epigenetic lesion that allows identifying those patients affected by brain tumours that have a longer life expectancy.

The discoveries in the cellular and molecular biology of cancer, the development of drugs against specific genetic mutations, and the emergence of immunotherapy are allowing the cure or improvement of the quality of life and life expectancy of patients with tumours.

However, there is a type of cancer that resists this encouraging news: the brain tumour.

This tumour, which is not born from neurons but from support cells named glial, represents a sad exception.

The mortality of brain cancer is around 85% within two years since it's diagnosis.

It is, therefore, an area of intense biomedical research.

The group of Dr. Manel Esteller, Director of the Josep Carreras Research Institute, ICREA Researcher and Professor at the University of Barcelona, has published this finding in the journal Acta Neuropathologica.

The research describes an epigenetic lesion that allows identifying those patients with brain tumours of good prognosis, 15% of remaining cases that will have prolonged survival.

"We began the study looking for genes with regulatory functions of genome expression that lost their activity in cancer. We identified a particular gene called NSUN5 of which we knew almost nothing about its function," explained Dr. Esteller about the research in Acta Neuropathologica.

"What surprised us most from the beginning was that its alteration, among the many types of tumours of the human body, was almost exclusive to gliomas, a type of brain cancer. We investigated it in laboratory cells and experimental models. When we got to analyse its impact on patients with glioma, we realised the importance of the finding.

"The epigenetic lesion of NSUN5, independently to other biomarkers, predicted that minority percentage of patients who will be doing well. It was astonishing since most of the time we discover factors that indicate tumours that will go bad.

"Mechanically, it seems that by the evolutionary selection, a brain tumour that is about to become extinct ends up causing the alteration of NSUN5. Then, NSUN5 'freezes' as if standing in time so that cancer progresses less and survival lengthens.

"Microenvironment factors surrounding the glioma such as lack of oxygen and lack of local nutrients contribute to induce NSUN5's inactivation. This process allows the tumour not to die, but grow so little that the patient shows a good prognosis. Therefore, we now have a marker that allows us to predict 15% of cases with good clinical course. 

"Furthermore, it would be exceptional to convert 85% of the remaining cases into patients who 'touching' the NSUN5 gene also had extended survival. We still don't know how to do it, but it deserves to be investigated carefully." concludes the researcher.

Source: Josep Carreras Leukaemia Research Institute